ERYTHROMYCIN ointment

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)

Commercializzato da:

MWI

INN (Nome Internazionale):

Erythromycin

Composizione:

Erythromycin 5 mg in 1 g

Via di somministrazione:

OPHTHALMIC

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N.gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

Dettagli prodotto:

Sterile Erythromycin Ophthalmic Ointment USP, 0.5% is available as follows: 3.5 g (1/8 oz) sterile tamper-resistant tube (NDC 13985-605-03)

Stato dell'autorizzazione:

Abbreviated New Drug Application

Scheda tecnica

ERYTHROMYCIN- ERYTHROMYCIN OINTMENT
MWI
----------
APEXA™
ERYTHROMYCIN
OPHTHALMIC OINTMENT USP, 0.5%
STERILE
RX ONLY
DESCRIPTION:
Erythromycin Ophthalmic Ointment belongs to the macrolide group of
antibiotics. It is
basic and readily forms a salt when combined with an acid. The base,
as crystals or
powder, is slightly soluble in water, moderately soluble in ether, and
readily soluble in
alcohol or chloroform. Erythromycin ((3R*, 4S*, 5S*, 6R*, 7R*, 9R*,
11R*, 12R*, 13S*,
14R*)-4-[(2,6-dideoxy-3-C-methyl-3-_0_-methyl-α-L-ribo-hexopyranosyl)-oxy]-14-ethyl-
7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D-
xylo-hexo-pyranosyl]oxy]oxacyclotetradecane-2,10-dione)) is an
antibiotic produced
from a strain of _Streptomyces erythraeus._
It has the following structural formula:
Molecular Formula: C
H
NO
Molecular Weight: 733.94
Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base
of mineral oil
and white petrolatum.
CLINICAL PHARMACOLOGY:
_MICROBIOLOGY:_ Erythromycin inhibits protein synthesis without
affecting nucleic acid
synthesis. Erythromycin is usually active against the following
organisms _in vitro_ and in
clinical infections:
37
67
13
_Streptococcus pyogenes_ (group A β-hemolytic)
Alpha-hemolytic streptococci (viridans group)
_Staphylococcus aureus,_ including penicillinase-producing strains
(methicillin-
resistant staphylococci are uniformly resistant to erythromycin)
_Streptococcus pneumoniae_
_Mycoplasma pneumoniae_ (Eaton Agent, PPLO)
INDICATIONS AND USAGE:
For the treatment of superficial ocular infections involving the
conjunctiva and/or cornea
caused by organisms susceptible to erythromycin.
For prophylaxis of ophthalmia neonatorum due to _N. gonorrhoeae_ or
_C. trachomatis._
The effectiveness of erythromycin in the prevention of ophthalmia
caused by
penicillinase-producing _N.gonorrhoeae_ is not established.
For infants born to mothers with clinically apparent gonorrhea,
intravenous or
intramuscular injections of aqueous crystalline penicillin G sh